Navigation Links
SyntheMed To Present at the AdvaMed 2008 MedTech Conference

ISELIN, N.J., Sept. 18 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today that it was selected to present at the AdvaMed 2008 MedTech conference being held in Washington, D.C. on September 21-24, 2008. Robert P. Hickey, President and CEO of SyntheMed, is scheduled to present on Wednesday, September 24, at 9:30 a.m. Mr. Hickey's PowerPoint presentation may be viewed at for thirty days after the presentation.

The purpose of the AdvaMed 2008 MedTech conference is to provide the opportunity for companies in the life sciences sector to present to an elite audience of potential investors, strategic partners and business collaborators. The selection of presenting companies is based on such criteria as: stage of product development, partnering opportunities, potential for licensing technology, intellectual property, timing of next capital raise, and overall appeal to the audience.

About AdvaMed

AdvaMed is the world's largest medical technology trade association representing over 1,600 medical technology innovators, manufacturers of medical devices, diagnostic products and medical information systems.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products, and other surgical implants. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.

SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
2. SyntheMed Files Universal Shelf Registration
3. SyntheMed to Present at the Acumen BioFin Conference
4. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
5. eResearchTechnology, Inc. to Present at the UBS Global Life Sciences Conference on September 23rd, 2008
6. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
7. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference
9. BioVex to Present at the UBS Global Life Sciences Conference
10. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
11. CryoLife to Present at UBS Global Life Sciences Conference
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):